BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 23, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» First-in-class drug-Fc conjugate shows efficacy in preclinical cancer models
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
First-in-class drug-Fc conjugate shows efficacy in preclinical cancer models
Nov. 8, 2023
CD73 (NT5E) contributes to cancer cell proliferation, migration and tumor angiogenesis by limiting immune response in the tumor microenvironment.
BioWorld Science
Conferences
Society for Immunotherapy of Cancer
Cancer
Immuno-oncology